Open AccessReal-life efficacy and safety of biosimilar adalimumab (ZRC-3197) in patients with plaque psoriasis: A tertiary care center experience
Author(s) -
Ajay Chopra,
Debdeep Mitra,
Reetu Agarwal,
Neerja Saraswat,
Pooja Chemburkar,
Loknandini Sharma
Publication year - 2020
Publication title -
indian dermatology online journal
Language(s) - English
Resource type - Journals
eISSN - 2249-5673
pISSN - 2229-5178
DOI - 10.4103/idoj.idoj_120_19
Subject(s) - medicine , adalimumab , dermatology life quality index , psoriasis , tolerability , psoriasis area and severity index , biosimilar , plaque psoriasis , adverse effect , discontinuation , dermatology , quality of life (healthcare) , rheumatoid arthritis , nursing
Adalimumab is proven to be safe and effective in treating plaque psoriasis. A biosimilar adalimumab (ZRC-3197; Exemptia™) - approved by Indian Regulators in 2014 - is a 'fingerprint match' of the reference adalimumab in terms of purity, potency, safety, and clinical efficacy. While reference adalimumab remains unavailable, this biosimilar adalimumab (bADA) serves as an accessible, cost-effective option for Indian patients. This is a first-hand, prospective, real-life data on the clinical use of bADA in Indian patients with plaque psoriasis.